UNSPSC 51373314: Acetaminophen/oxycodone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51373314 Acetaminophen/oxycodone (Commodity) covers pharmaceutical products that state and local governments procure through competitive bidding and cooperative purchasing agreements, though recent solicitations tagged under this code show broader activity in naloxone distribution, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription programs rather than acetaminophen/oxycodone combinations specifically. State and local issuing bodies purchasing under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida procures naloxone and drug deactivation systems through fixed-price IFB contracts, while the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription fulfillment models, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) coordinates generic pharmaceutical supply across participating state and local government facilities in Minnesota and Oregon. Vendors must comply with FDA requirements, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, E-Verify eligibility verification, drug-free workplace certification, and comprehensive insurance coverage including commercial general liability and professional liability policies.

Recent activity appears concentrated in the upper Midwest and South. The Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products closed March 26, 2026, requiring vendors to submit detailed National Drug Code information and pricing through authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with contract effectiveness July 1, 2026 and evaluation weighted 75 percent on price competitiveness. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries through July 26, 2023 (note: this due date appears erroneous in the source). The Texas Health and Human Services Commission's Request for Information HHS0017013, posted April 3, 2026, seeks vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization arrangements, representing exploratory procurement that will inform future formal solicitation strategy.